Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioRestorative Therapies, Inc. (BRTX)

BioRestorative Therapies appoints Donald J. Currie as director, fills August 2026 vacancy

Neutral Impact 2 of 5 leadership Written later

BioRestorative Therapies, Inc. appointed Donald J. Currie as a Class I director effective October 7, 2026, filling the seat vacated by Katharyn Field's resignation effective August 31, 2026. Mr. Currie also joined the Nominating and Corporate Governance and Compensation Committees, and the Board deemed him independent under Nasdaq rules. The change is a routine board appointment with no financial results or guidance included.

Key points

  • Donald J. Currie appointed Class I director on October 7, 2026, serving until the 2027 annual meeting
  • Currie added to the Compensation Committee and Nominating and Corporate Governance Committee
  • Currie to receive a cash fee of CAD $2,000 per month and will not join the standard non-employee director compensation program

The filing

CompanyBioRestorative Therapies, Inc. (BRTX)
Form8-K, current report
Filed with the SECOct 9, 2026, 4:05 PM ET
Accession number0001213900-26-108467

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.